Novartis’ TREM2 drug fails Phase 2 ALS trial
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Novartis’ TREM2 drug fails Phase 2 ALS trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Reuters, Fierce Biotech, Investor's Business Daily and Bloomberg.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 61d ago.
Quick answers
Why is "Novartis’ TREM2 drug fails Phase 2 ALS trial" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (5)
- Novartis halts ALS drug development after mid-stage trial failure Reuters · 61d ago
- Novartis ends ALS program after phase 2 flop, adding to R&D woes Fierce Biotech · 61d ago
- Novartis Suffers Another Setback After Stock-Rocking Failures Investor's Business Daily · 61d ago
- Novartis Experimental Drug for ALS Fails in Another Pipeline Hit Bloomberg.com · 61d ago
- Novartis’ TREM2 drug fails Phase 2 ALS trial Endpoints News · 61d ago
Topics
Related trends
Brain Implants Give A.L.S. Patients the Voice to Speak and Sing
A 2026 Nature Medicine study showed an ALS patient used an implanted brain-computer interface at home for nearly two years, producing 183,060 sentences at 56 words per minute, while a separate 2025 system recreated his pre-illness voice and let him sing.
Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
Medical experts are stunned after the promising cholesterol drug pelacarsen unexpectedly fails a key study, leading to its abandonment.
F.A.A. to Phase Out Floppy Disks in Air Traffic Control Towers
The Federal Aviation Administration plans to phase out floppy disks from air traffic control systems.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Rebecca Gayheart details Eric Dane’s final week of life: ‘Had no idea that was it’
Rebecca Gayheart details Eric Dane's final week and brutal ALS decline in her first broadcast appearance following his death.
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.